Try our beta test site

Endocannabinoids in End Stage Renal Disease

This study has been completed.
Information provided by (Responsible Party):
Allon Friedman, Indiana University Identifier:
First received: November 18, 2011
Last updated: August 21, 2012
Last verified: August 2012
To investigate the relationship between dietary intake, body habitus, and endocannabinoid levels in end stage renal disease patients as compared to matched controls.

End Stage Renal Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Indiana University:

Enrollment: 30
Study Start Date: February 2012
End stage renal disease patient
Matched controls


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Hemodialysis patients healthy control subjects

Inclusion Criteria:

  • hemodialysis patient, able to give informed consent

Exclusion Criteria:

  • hospitalization in past 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Allon Friedman, Assistant Professor of Medicine, Indiana University Identifier: NCT01477515     History of Changes
Other Study ID Numbers: ANF-1
Study First Received: November 18, 2011
Last Updated: August 21, 2012

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency processed this record on March 30, 2017